Mapping breast cancer care patterns in FARO member countries: A survey

Aims This electronic survey aimed to elucidate clinicopathological features and management trends of breast cancer across the Asian region, identify existing gaps in care, and inform strategies to enhance outcomes. Methods A 50-item online questionnaire was developed and distributed to the Federation of Asian Organizations for Radiation Oncology (FARO) scientific, research, education, and leadership committee, as well as FARO council members. Based on 31 respondents from 12 of 14 FARO member countries , the survey assessed breast cancer incidence, patho-morphology, prognostic and predictive factors, registry/screening status and multimodality management. Results were analyzed using descriptive statistics, with proportions reported and comparisons made between observations. Findings reflect respondent-reported institutional patterns, not validated national statistics. Results Key findings revealed an increasing incidence of breast cancer across the region. Early-stage diagnosis was more prevalent in countries with national screening programs (Japan, South Korea, Singapore). Utilization of genetic testing and breast reconstruction was reported as low (under 20% of patients). Radiotherapy access was generally reported as adequate, with 64.5% of respondents reporting a time interval of less than six weeks between consultation and treatment initiation. Country-wise analysis revealed a distinct East-West divide in stage at presentation, with East Asian countries diagnosing predominantly Stage I disease, while South and Southeast Asian countries diagnosed predominantly stage III disease. Significant income-based inequities in access to targeted therapies were observed. Conclusion The observed disparities highlight the need for national and regional policy harmonization and collaborative clinical trials. The ongoing development of a FARO regional breast cancer database will be crucial for supporting future research and quality improvement initiatives.